Literature DB >> 9231067

Factors controlling the efficiency of cationic lipid-mediated transfection in vivo via intravenous administration.

F Liu1, H Qi, L Huang, D Liu.   

Abstract

The factors controlling the transfection efficiency of cationic lipid carrier systems following intravenous administration are poorly understood. Using N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium chloride (DOTMA) combined with Tween 80 as a carrier system and cDNA of luciferase or beta-galactosidase gene as a reporter, we investigated the importance of DOTMA to DNA ratio and the ratio of DOTMA to Tween 80 in the lipid formulation in determining the site and level of transgene expression following intravenous administration. The data show that all of the internal organs, including lung, liver, spleen, heart and kidneys, expressed the transgene upon systemic administration into animals with 25 micrograms of plasmid DNA when complexed with DOTMA-Tween 80 lipid formulation. The transfection efficiency was dependent on both DOTMA to DNA, and DOTMA to Tween 80 ratios. Among the organs examined, the lung appeared to be more transfectable than other organs. A better transfection activity was obtained with higher DOTMA to DNA and DOTMA to Tween 80 ratios. Time-response curve shows that gene expression was transient with a maximal level between 10 and 24 h after injection. Results from tissue distribution studies with 125I-labeled plasmid DNA and Southern analysis suggest that the transient expression is the result of the loss of transgene from the transfected cells. These results suggest that cationic lipid-based delivery systems can be efficient for gene delivery if the composition of the DNA-lipid complexes is properly controlled.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9231067     DOI: 10.1038/sj.gt.3300424

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  26 in total

Review 1.  New directions in liposome gene delivery.

Authors:  N S Templeton; D D Lasic
Journal:  Mol Biotechnol       Date:  1999-04       Impact factor: 2.695

Review 2.  In vivo characteristics of cationic liposomes as delivery vectors for gene therapy.

Authors:  Sandrine A L Audouy; Lou F M H de Leij; Dick Hoekstra; Grietje Molema
Journal:  Pharm Res       Date:  2002-11       Impact factor: 4.200

Review 3.  Targeted delivery of nucleic-acid-based therapeutics to the pulmonary circulation.

Authors:  Ramalinga Kuruba; Annette Wilson; Xiang Gao; Song Li
Journal:  AAPS J       Date:  2009-01-09       Impact factor: 4.009

Review 4.  Nonviral gene delivery: principle, limitations, and recent progress.

Authors:  Mohammed S Al-Dosari; Xiang Gao
Journal:  AAPS J       Date:  2009-10-16       Impact factor: 4.009

Review 5.  DNA-antiviral vaccines: new developments and approaches--a review.

Authors:  M Giese
Journal:  Virus Genes       Date:  1998       Impact factor: 2.332

Review 6.  Gene therapy.

Authors:  M A Kay; D Liu; P M Hoogerbrugge
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

7.  Optimizing cationic and neutral lipids for efficient gene delivery at high serum content.

Authors:  Chia-Ling Chan; Kai K Ewert; Ramsey N Majzoub; Yeu-Kuang Hwu; Keng S Liang; Cecília Leal; Cyrus R Safinya
Journal:  J Gene Med       Date:  2014 Mar-Apr       Impact factor: 4.565

8.  The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome.

Authors:  Weili Yan; Leaf Huang
Journal:  Int J Pharm       Date:  2008-10-15       Impact factor: 5.875

9.  DNA as therapeutics; an update.

Authors:  P Saraswat; R R Soni; A Bhandari; B P Nagori
Journal:  Indian J Pharm Sci       Date:  2009-09       Impact factor: 0.975

10.  Metabolically stabilized long-circulating PEGylated polyacridine peptide polyplexes mediate hydrodynamically stimulated gene expression in liver.

Authors:  C A Fernandez; N J Baumhover; J T Duskey; S Khargharia; K Kizzire; M D Ericson; K G Rice
Journal:  Gene Ther       Date:  2010-08-19       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.